Download Richard - Premier Clinical Research

CURRICULUM VITAE
April 2011
NAME AND ADDRESS:
Richard G. Gower, M. D., FACAAI, FAAAAI, FACP
823 W. 7th Avenue
Spokane, WA 99204
Phone: 509 879 4523 cell
Email: [email protected]
PROFESSIONAL STATUS
Current:
Marycliff Allergy Specialists, PS, 2006-Present
Allergy/Asthma/Clinical Immunology
Clinical Associate Professor of Medicine, University of WA
823 West 7th Avenue
Spokane, WA 99204
Phone: (509) 838 3655
Fax: (509) 838 1952
Email: [email protected]
.
Sub Investigator for:
Pulmonary and Research Associates
104 West Fifth Avenue, Suite 400 West
Spokane, WA 99204
Past:
Partner-Rockwood Clinic, 1977-2006
400 East 5th Avenue
Spokane, WA 99202
Phone: (509) 838 2531
UNIVERSITIES ATTENDED:
Wabash College, Crawfordsville, Indiana, 1964-1968
Major: Biology
Minor: Chemistry
A. B. Degree Cum Laude
University of Colorado School of Medicine,
Denver, Colorado, 1968-1972
Doctor of Medicine Degree, May 24, 1972
PROFESSIONAL TRAINING:
Externship:
Radiology. General Rose Memorial Hospital,
Denver, Colorado, summer 1970
Rural Preceptorship: General Practice. Craig, Colorado, summer 1971
Internship:
Straight Medicine. University of Miami Affiliated
Hospitals, Miami, Florida. Hospitals: Jackson Memorial,
Veterans Administration, National Children's Cardiac
Hospital, July 1972 - June 1973
Residency:
Internal Medicine. University of Miami Affiliated Hospitals,
Miami, Florida. Hospitals: Jackson Memorial,
Veteran's Administration, Mt. Sinai, July 1973 - June 1975
Fellowship:
Allergy and Clinical Immunology, Vasculitis.
University of Colorado Medical Center
Hospitals: Colorado General, Veterans Administration,
Denver General, National Jewish Hospital, Fitzsimmons Army
Hospital, Children's Asthma Research Institute and Hospital,
July 1975 - June 1977
EXTRACURRICULAR ACADEMIC TRAINING:
Wabash College:
Laboratory Instructor, invertebrate zoology, fall semester 1966
Laboratory Instructor, morphogenesis of vertebrates, spring
semester, 1967
Faculty Instructor, general biology, 1967 - 1968
Medical School:
Research in radiation and health physics, Department of
Radiology, University of Colorado Medical School, summer
1968
Research fellowship grant for work in tagging red blood cells with
chromium-51 and developing a liquid scintillation counting
technique for counting the tagged globin portion of the
hemoglobin molecule, Department of Radiology, University
of Colorado Medical Center, summer 1969
Morgue diener, Department of Pathology, General Rose Memorial
Hospital, Denver, Colorado, summer 1970
Richard G. Gower, M.D.
2
Internship-Residency:
Emergency Room Work (extracurricular):
Memorial Hospital, Hollywood, Florida, 1973, 1974, 1975
South Miami Hospital, Miami, Florida, 1974, 1975
Lauderdale Lakes Hospital, Ft. Lauderdale, Florida, 1974, 1975
Fellowship:
Primary coordinator of an ongoing vasculitis study group
Attending physician in Colorado General's Allergy Clinic, 1976-1977
Emergency Room Work (extracurricular), 1975-1977
HONORS AND AWARDS:
Wabash College
College Scholarship, 1964 - 1966
Alfred B. Sloan Scholar, 1966 - 1968
President, Campus Center Board, 1967 - 1968
Phi Beta Kappa, 1968
Medical School
Glen E. Cheley Scholarship, 1968 - 1969
Health Professions Scholarship, 1968 - 1969
Awarded certificate from American College of Surgeons, Colorado
Trauma Committee, Immediate Emergency Care Course, 1969
Medical student representative for the basic sciences from the
University of Colorado School of Medicine to National Student
Research Forum (SAMA-UTMB) at Galveston, Texas, April 1969
Medical Practice
The National Registry of Who’s Who, Life Member, 2000 edition
Medical Practice
Recognized in the “Guide to America’s Top Physicians” by SLD Industries, Consumers
Research Council of America, 2009
CERTIFICATION:
National Board of Medical Examiners Parts 1, 2, and 3 (Diplomate)
Florida State Boards
Colorado Basic Science Boards
American Board of Internal Medicine - Board Certified 1975
(Diplomate)
American Board of Allergy and Immunology - Board Certified 1977
(Diplomate)
American College of Allergy, Asthma, and Immunology – Fellow, 1986
Richard G. Gower, M.D.
3
American College of Physicians – Fellow, 2006
STATE LICENSES:
Washington, Florida (inactive), Colorado (inactive)
HOSPITAL STAFF PRIVILEGES:
Sacred Heart Medical Center, Spokane, Washington
Deaconess Medical Center, Spokane, Washington
SOCIETY AFFILIATIONS:
American College Allergy/Asthma/Immunology (Fellow)
American Academy of Allergy/Asthma/immunology (Fellow)
American College of Physicians (Fellow)
American Lung Association
American Medical Association
Association of Allergists from India
Association of Pharmaceutical and Physician Investigators
Intermountain West Allergy Association
Northwest Rheumatism Society
Phi Beta Kappa
Spokane Society of Internal Medicine
Spokane County Medical Society
Washington State Medical Association
Washington State Society of Allergy/Immunology
Washington State Society of Internal Medicine
Washington State Thoracic Society
Western Society of Allergy, Asthma and Immunology
PROFESSIONAL APPOINTMENTS:
Attending Physician, Sacred Heart Medical Center,
1977 - Present
Attending Physician, Deaconess Medical Center,
1977 - Present
Attending Physician, St. Luke's Hospital, 1977 - 1993
Chairman, Department of Medicine, St. Luke's Hospital,
1979 - 1981 and 1988 - 1990
Trustee, St. Luke's Hospital, 1981 - 1982
Richard G. Gower, M.D.
4
TEACHING AFFILIATIONS
Clinical Associate Professor of Medicine, University of Washington School of
Medicine - attending/lecturer for Internal Medicine Residency at Sacred
Heart Hospital and Deaconess Hospital in Spokane, Washington
COMMUNITY AND PROFESSIONAL SERVICES:
Past President, American College of Allergy, Asthma, and Immunology,
2010-2011
Immediate Past President, American College of Allergy, Asthma, and Immunology,
2009-2010
President, American College of Allergy, Asthma, and Immunology, 2008-2009
President-Elect, American College of Allergy, Asthma, and Immunology, 2007-2008
Vice President, American College of Allergy, Asthma, and Immunology, 2006-2007
Treasurer, American College of Allergy, Asthma, and Immunology,
2003-2006; Treasurer, ACAAAI Foundation, 2003-2006
Executive Committee, American College of Allergy, Asthma, and Immunology,
2000-2002 and 2003-2008.
Member, ACAAI Investment Oversight Committee, 2003-2008
Regent, Board of Regents, American College of Allergy, Asthma, and
Immunology, 1999-2002
Speaker, House of Delegates, American College of Allergy, Asthma, and
Immunology, 1997-1999; Vice-Speaker, 1994-1997
Chairman, Health System Reform Committee, American Society
of Internal Medicine, Washington, D. C., 1993 - 1995
Member 1987 – 1995
Chairman, American College of Allergy, Asthma, and Immunology Task
Force on Education of Fellows in Training and Primary Care, 1998-2000
Member, HEDIS Task Force, American College of Allergy, Asthma, and
Immunology, 2004-present
Richard G. Gower, M.D.
5
Member, American College of Allergy, Asthma, and Immunology CME
Committee, 1997-2000; Annual Program Committee, 1997-1998
Chairman, JCAAI Membership Recruitment Committee, 2002-2006
Member, Joint Council of Allergy, Asthma and Immunology, 2001-2006; 2007-2008
President, Western Society of Allergy, Asthma, and Immunology,
1997-1998. Immediate Past President, 1998-1999, Executive
Council, 1993-2000
President, Intermountain West Allergy Association, 2000-2001;
Vice-President, 1997-2000, Program Chairman, 1998, Immediate Past
President, 2001-2002
Chairman, Managed Care Committee, American College of
Allergy, Asthma, and Immunology, 2001-2002. Member, 1994-2002
Member, ACAAI Managed Care Strike Force, 1994-1995
Chairman, Professional Allergy/Immunology Education Committee, ACAAI,
2001-2004; member, 2000-2006
Chairman, ACAAI Public Relations Network, 2002-2005, Vice-Chairman, 2000-2002;
Member, 1993-present
Program Co-Chairman, American College of Allergy, Asthma and
Immunology, “Meeting the Challenge of Change”, Keystone, Colorado,
July 16-18, 1999
Member, Judicial Council of Washington State Medical Association, 1995-1998
Member, Membership Recruitment Committee, American College of Allergy,
Asthma, and Immunology, 1998-2005
Member, Professional Education Council, ACAAI, 2001-2005
Consultant:
Richard G. Gower, M.D.
1. International Asthma Advisory Board, Schering-Plough
International, Inc.; September 5-7, 1996, Stockholm, Sweden
2. National Asthma Advisory Board, Astra Pharmaceuticals,
August 22-25, 1996, Colorado Springs, Colorado.
3. Biaxin Advisory Board, Abbott Laboratories, September
27-29, 1996, Rancho Mirage, California.
4. Asthma Management Guidelines, Healthplus of Washington,
September, 1996.
6
Consultant: (cont’d)
5. American Lung Association of Washington, Washington
State Asthma Project, Professional Education Task Force,
June 1997 - Present.
6. Regional Pediatric Asthma Advisory Board, Merck, July 24-26,
1997, Seattle, Washington
7. Asthma Management Guidelines for Children, Blue Cross of
Washington, November, 1997.
8. Asthma Disease Management Program, Group Health
Northwest, December 18, 1997.
9. Allergic Disease Management, Key Pharmaceuticals, June
18-20, 1998, San Francisco, California
10. Asthma Disease Management, Key Pharmaceuticals,
February 12-15, 1998, New York, New York
11. Asthma Disease Management, Rhone-Poulenc Rorer,
February 19-22, 1998, Tampa, Florida
12. Editorial Board, Key Pharmaceuticals, Asmanex
Twisthaler: A New Inhaled Corticosteroid for the
Treatment of Asthma: June 3-4, 1999, Chicago, Ill.
August 25-27, 1999, San Francisco, California
13. Allergic Rhinitis and Sinusitis Management Guidelines,
Premera of Washington, January 2001
14. National Allergist Advisory Board, Aventis,
2001, Coeur d’Alene, Idaho, 2002, Vaancouver, BC, 2002,
Kohler, Wisconsin, 2003, San Diego, CA, 2005
15. Novartis Ophthalmic, Key Biscayne, Florida, February 8-10 2002
16. Respiratory Advisory Board Meeting, IVAX Laboratories,
Miami, Florida, February 15-17, 2002
17. ABRS National Consultant Meeting, Scottsdale, AZ, Dec. 2004,
Sanofi Aventis
18. RESP Council, San Diego, CA, May 26-27 2005 and Dec. 16, 2005
19. ALCON Allergic Foundation Board, June 17, 2005, Chicago, Ill.
President, Inland Empire Allergy Forum, 1993-1999
Vice-President, Rockwood Clinic Medical Foundation (Research),
1988 –1998
Board of Directors, Inland Northwest Blood Center, 1993 - 1998
Secretary-Treasurer, 1997-1998
President, Washington State Society of Internal Medicine, 1986-1987
Executive Council: 1984 - 1987; 1994 -1999
Member, Washington State Asthma Project, 1997-2002
Richard G. Gower, M.D.
7
Planning and Building Committee, New Rockwood Clinic Multispecialty
Center, 1984-1987
Medical Director, Regional Systemic Lupus Erythematosus Support
Group, 1977 - 1991. Medical Advisor, 1977-1997
Specialty Advisory Council, Medical Service Corporation,
1993 - 2005
Delegate, Washington State Medical Association, 1987, 1990, 1993,
1994, 1997
Member, American College of Allergy, Asthma, and Immunology
Public Relations Program, 1990 - Present
Member, Public Awareness and Community Education Committee
Washington State Medical Association, 1987 - 1995
Program Chairman, Washington State Medical Association Annual
Meeting, Symposium on Allergy/Immunology, Spokane, Washington,
September 1986 and 1990.
Program Chairman, Washington State Medical Association/
Washington State Society of Internal Medicine Symposium,
Tacoma, Washington, September 18, 1987
Program Chairman, Rockwood Clinic Fall Medical Symposia,
1987 - 1990
Program Coordinator, Washington State Medical Association/
Washington Society of Internal Medicine Symposium on "The
Future of Medicine", Spokane, Washington, May 15, 1993
Initiated and implemented Immune Deficiency Support Group,
Spokane, Washington 1992
Initiated and implemented Rockwood Clinic/Hutton Elementary
School "Partners in Business Program," Spokane, Washington,1987 - 1992
Initiated and implemented Foreign Travel and Immunization Clinic,
Spokane, Washington, 1983.
Volunteer "Parent of the Year," Hutton Elementary School, 1992
Member, Independent Data Safety Monitoring Board, ISTA Pharmaceuticals, 2010
Editorial Board of Angioedema Journal, 2009-2011
Richard G. Gower, M.D.
8
PUBLICATIONS:
1.
"Ultraviolet-induced Changes in Residual Thermoluminescence from
Gamma-irradiated Lithium Fluoride." Richard G. Gower,
William R. Hendee, and Geoffrey S. Ibbott, Health Physics,
Vol. 17, 1969, pp. 607-611.
The above paper presented at:
National Student Research Forum at Galveston, Texas, April 1969
Southwestern and Rocky Mountain Division, American Association
for the Advancement of Science, Colorado Springs, Colorado,
May 1969
Rocky Mountain Radiological Society, Midsummer Conference,
Denver, Colorado, summer 1969
2.
"Leukocytoclastic Vasculitis - A Sequential Study of
Immunoreactants and Cellular Reactants After Histamine
Injection." Richard G. Gower, W. Mitchell Sams, E. George
Thorne, Peter F. Kohler, and Henry N. Claman, Journal of
Investigative Dermatology, 1977.
Paper presented at the American Academy of Dermatology,
Chicago, Illinois, December 1976 by Dr. Gower.
3.
"Small Vessel Vasculitis Associated with Hepatitis B Surface
Antigen," Richard G. Gower, William F. Sausker, Peter F.
Kohler, E. George Thorne, Rawle M. McIntosh, Journal of
Allergy/Clinical Immunology, Vol. 62, No. 4, October 1978.
Paper presented at the American Congress of Allergy, New York
City, New York, March 1977 by Dr. Gower.
4.
"Cerebral Vasculitis Associated with Pheochromocytoma," two case
reports by Richard G. Gower, M.D., in Dr. William M.
Manger's textbook, Clinical and Experimental Pheochromocytoma,
second edition, Chapter 7, pp. 335-339, Blackwell Science 1996.
Paper presented by Dr. Gower at:
Washington State Allergy Society Annual Meeting
Alderbrook, Washington, May 2, 1992.
Annual Aspen Allergy Conference, Aspen, Colorado, July 23, 1992.
American College of Allergy and Immunology, Chicago, Illinois,
November 14 - 16, 1992
Richard G. Gower, M.D.
9
.
Northwest Rheumatism Society Annual Meeting, Seattle,
Washington, April 30, 1993.
British Society of Allergy and Clinical Immunology,
Nottingham, England, August 2, 1993.
Western Society of Allergy and Immunology, Kona, Hawaii,
January 23 - 26, 1994.
5.
“Hypothalamic-Pituitary-Adrenal Axis Function During Treatment of Pediatric
and Adolescent Asthma with Beclomethasone Dipropionate or Fluticasone
Propionate”, Advances in Therapy, March/April 1997, Volume 14, No. 2.
6.
“Inhaled Mometasone Furoate Reduces Oral Prednisone Requirements While
Improving Respiratory Function and Health-Related Quality of Life in Patients
With Severe Persistent Asthma”: Journal of Allergy and Clinical Immunology,
November 2000, pp. 852-860
7.
“Insurance Coverage for H1 Antihistamines: Implications for Quality Health Care
and Public Safety”. Position Statement of the AAAAI, ACAAI, and JCAAI, co-author,
November 18, 2002.
“Reduction in Oral Corticosteriod Use with Mometasone Furoate Dry Powder
Inhaler Improves Health-Related Quality of Life in Patients With Severe
Persistent Asthma”, Jordana Schmier, Nancy Kline Leidy, and Richard G.
Gower, Jnl. Of Asthma, vol 40, No. 4, pp 383-393, 2003
8.
Paper Presented (poster) at European Respiratory Society, Stockholm, Sweden,
September 2002, by Dr. Gower
Paper Presented (poster) at Western Society of Allergy, Asthma, and Immunology,
Kona, Hawaii, January 2003 by Dr. Gower
9.
“Once-daily ciclesonide is effective and well-tolerated in the treatment of Adult and
Adolescent patients with mild-to-moderate Asthma”. Poster presentation, March
2005, AAAAI
10.
“Eradication of common pathogens at Days 2, 3, and 4 of moxifloxacin therapy in
patients with acute bacterial sinusitis”, BMC Ear, Nose and Throat Journal, website
as “Provisional PDF”, 2006, 6:8
11.
“A multi-site study evaluating patient perceptions of Olapatadine 0.2% in patients with
allergic conjunctivitis.” Poster presentation, Western Society of Allergy, Asthma, and
Immunology, January 2008.
12.
“Sub-lingual Immunotherapy: WAO Position Paper 2009.”
Richard G. Gower, M.D.
10
13.
“How GARD is integrating the WHO Noncommunicable Diseases action plan and
NCDnet: (Noncommunicable Disease Network)” 2009
14.
“Clinical Presentation, Diagnosis, and Treatment of Hereditary Angioedema: An
Overview”. Clinical Cornerstone. Focus on Angioedema. Vol. 10, Supplement 1. 2011
15.
“Current Medical Management of Hereditary Angioedema: Results From a Large Survey
of U.S. Physicians. Annals of Allergy, Asthma & Immunology.” 2011
16.
“Hereditary Angioedema Caused by C1-Esterase Inhibitor Deficiency: A Literature-Based
Analysis and Clinical Commentary on Prophylaxis Treatment Strategies.” World Allergy
Organization Journal. 2011 (In Process)
17.
Hereditary Angioedema Treatment: Consensus Paper. World Allergy Organization Journal.
2011 (In Process)
BOOK REVIEW:
Frozen Tears. John Strimas, M.D., published in Annals of Allergy, vol. 94, May 2005
SCIENTIFIC PUBLICATION REVIEW:
Journal reviewer for Annals of Allergy. 1995-present
Journal reviewer for Allergy and Asthma Proceedings. 2003-2007
Editorial Board of Angioedema Journal, 2009-present
“Management of Allergic and Nonallergic Rhinitis”, Evidence Report, New England
Medical Center Evidence-based Practice Center, 2001
“Rhinitis Severity Assessment” manuscript, supplement to “Rhinitis Parameters” 1998,
Joint Task Force on Practice Parameters, 2002
Device Selection and Outcomes of Aerosol Therapy:
ACCP/ACAAI Evidence-Based Guidelines
Dolovich, MB et al. February, 2004
“Asthma Management and the Allergist: Better Outcomes at
Lower Cost”, Blue Book, March 2003
“A Comparison of Delivery Devices: Small Volume Nebulizers
and Metered Dose Inhalers”. B. Chipps et al, January 2004
“Sinusitis Practice Parameters”. ACAAI, S. Spector et al, 2004
Richard G. Gower, M.D.
11
“When is prophylaxis for hereditary angioedema necessary?”. Annals of Allergy,
Craig et.al. 2009
“Sub-Lingual Immunotherapy WAO Position Paper 2009”. WAO Position Paper,
Canonica et. al. 2009
“Hereditary Angioedema Caused by C1-Esterase Inhibitor Deficiency: A Literature-Based
Analysis and Clinical Commentary on Prophylaxis Treatment Strategies”.
Gower, et al. WAO Journal. 2011
“Current medical management of hereditary angioedema: results from a large survey of
US physicians”. Riedl et. al. 2011. Annals of Allergy 2011
“Clinical Presentation, Diagnosis, and Treatment of Hereditary Angioedema: An
Overview”. R. Gower and E.S. Levitch. Clinical Cornerstone Supplement. 2011
“Evidence-Based recommendations for the Therapeutic Management of angioedema due
to hereditary C1- inhibitor deficiency. (a consensus report of international
working group). Cicardi, et. al. WAO 2011. In process.
Richard G. Gower, M.D.
12
PRESENTATIONS:
1.
"Treatment of Stinging Insect Sensitive Patients with Hymenoptera
Venom Desensitization."
Presentation on April 24, 1981, at Snake River Medical Forum,
Lewiston, Idaho.
2.
"Fiberoptic Rhinopharyngolaryngoscopy in the Practice of Clinical
Immunology: A study of 80 Patients."
Presentation in May 1986 at annual Washington State Allergy
Society Meeting, Ocean Shores, Washington.
3.
"Systemic Lupus Erythematosus."
Presentation in September 1986 at Washington State Medical
Association annual meeting, Spokane, Washington.
4.
"Are Immunological Tests Worthwhile?"
Presentation on November 14, 1987, at Rockwood Clinic Fall
Medical Symposium, Spokane, Washington.
Presentation on March 24, 1995, at annual Montana Big Sky
Pulmonary Conference, Bozeman, Montana.
Presentation on September 21, 2001, at Grand Rounds Conference,
Bozeman, Montana
5.
"Diagnosis and Treatment of Asthma."
Presentation on May 20, 1988, at Snake River Medical Forum,
Lewiston, Idaho
Presentation on February 25, 1989, at annual Spokane Society of
Internal Medicine Symposium, Spokane, Washington.
6.
"Atopic Dermatitis."
Presentation on November 4, 1989, at Rockwood Clinic Fall
Medical Symposium, Spokane, Washington.
7.
"Asthma, the Nocturnal Disease."
Presentation on October 12, 1992, at Medical Grand Rounds,
Kalispell, Montana
8.
"Asthma Therapeutics: The Controversies Surrounding
Bronchodilators and Anti-inflammatory Medicines."
Presentation on February 17, 1993, for the American Lung
Association of Washington, Spokane, Washington.
Richard G. Gower, M.D.
13
9.
"Living with Allergies."
Presentation on March 3, 1993, to general public for Rockwood
Clinic's "Health Talks" series in Spokane, Washington.
10.
"The Role of Nasal Steroids and Antihistamines in Allergic
Rhinitis"
Presentation on March 17, 1993, for Idaho Pharmacists in
Pullman, Washington.
Presentation on March 24, 2001 to regional physicians in Seattle, WA.
11.
"Asthma and Emphysema - Myths and Facts."
Presentation on April 15, 1993, for American Lung Association of
Washington in Spokane, Washington.
12.
"Advances in the Treatment of Allergic Rhinitis."
Presentation on July 24, 1993, in Coeur d'Alene, Idaho.
Presentation on September 13, 2001, in Lewiston, Idaho.
13.
"Assessment and Treatment Costs in COPD: Cost Effective Care
Under Capitation."
Presentations on November 4, 1993, and February 3, 1994, in
Spokane, Washington.
Presentation on March 25, 1995, at annual Montana Big Sky
Pulmonary Conference, Bozeman, Montana.
.
14.
"Immunoglobulin Therapy for Immunodeficiency States."
Presentation on March 21, 1994, for University of Washington
School of Medicine Sub-Specialty Conference, Spokane, Washington.
Presentation on February 28, 1997, for Medical Grand Rounds at Providence
Hospital, Anchorage, Alaska
15.
"Hay Fever and Sinus Problems."
Presentation on April 14, 1994, and January 15, 1997,to general public for
Rockwood Clinic's "Health Talks" series in Spokane, Washington.
16.
"Allergic Rhinitis and Sinusitis."
Presentation on May 19, 1994, for North Idaho Medical Association, Lewiston, Id.
17.
"Immunizations and Medications In Lupus Patients Traveling Abroad."
Presentation on May 20, 1994, for the American Lupus Society
in Spokane, Washington.
18.
"Challenging Cases in Allergy and Immunology."
Moderator and Discussant on September 21, 1994, in Coeur d'Alene, Idaho.
Richard G. Gower, M.D.
14
19.
"Vasculitis and Autoimmune Disease States."
Presentation on October 8, 1994, for the American Lupus Society
in Spokane, Washington.
20.
"Medications and Asthma." Washington Lung Association.
Presentation on October 26, 1994, for Washington Lung Association,
Spokane, Washington.
21.
"Primary Care Issues in the Management of Asthma."
Teleconference presentations to physicians and staff in:
Toccoa, Georgia, on December 6, 1994
Inglewood, California, on December 8, 1994
Lewiston, Idaho, on February 7, 1995
Olympia, Washington on February 10, 1995
Great Falls, Montana, on February 15, 1995
Sparks, Nevada, on March 14, 1995
Tacoma, Washington, on March 21, 1995
Seattle, Washington, on March 21, 1995
Bellevue, Washington, on March 22, 1995
Spokane, Washington on March 29, 1995
Spokane, Washington, on March 30, 1995
Seattle, Washington on April 6, 1995
Belfair, Washington, on April 18,1995
Vancouver, Washington, on May 4, 1995
Coeur D'Alene, Idaho, on July 21, 1995
Spokane, Washington, on August 30, 1995
Citrus Heights, California, on November 29, 1995
22.
"Treatment Options for Upper and Lower Respiratory Tract Infections in Clinical
Practice” Presentations on:
December 12, 1994, for community physicians in Missoula, Mt.
April 25, 1995, for physicians' assistants in Spokane, Washington
December 6, 1995, for community physicians in Spokane, Wa.
March 27, 1996, for regional physicians in Coeur d'Alene, Idaho.
May 29, 1996, for regional physicians in Moses Lake, Wa.
October 16, 1996, for regional physicians in Missoula, Mt.
October 24, 1996, for community physicians in Spokane, Wa.
October 30, 1996, for community physicans in Spokane, Wa.
November 14, 1996, for regional physicians in Coeur d'Alene, Id.
December 9, 1996, for regional physicians in Moses Lake, Wa.
December 18, 1996, for regional physicians in Whitefish, Montana
February 1, 1997, for regional physicians in Richland, Wa.
February 27, 1997, for regional physicians in Fairbanks, Alaska
February 28, 1997, for regional physicians in Anchorage, Alaska
"Itches, Ouches, and Rashes."
Presentation May 10, 1995, to public for Rockwood Clinic's "Health Talks"
series in Spokane, Washington.
23.
Richard G. Gower, M.D.
15
24.
"The Role of Theophylline in Asthma Therapy in 1995."
Presentation June 14, 1995, for community physicians in Spokane, Washington
25.
"An Update in the Treatment Options for Sinusitis."
Presentation July 29, 1995, for regional physicians in Spokane, Washington.
26.
"Hypersensitivity Vasculitis: Diagnosis, Management, and Systemic Associations"
Presentation September 29, 1995, for Washington State Medical Association
annual meeting, Spokane, Washington.
27.
"Antiviral Therapy Update."
Presentations October 25, 1995, and January 16, 1996, for regional physicians
in Spokane, Washington.
28.
"Treatment Modalities in Allergic Rhinitis."
Presentation March 6, 1996, for regional physicians in Plummer, Idaho.
29.
"Living With Lupus."
Presentation March 13, 1996, for community patients and family members in
Spokane, Washington.
30.
"Allergic Rhinitis: The Association with Sinusitis and Otitis Media."
Presentation April 24, 1996, for regional physicians in Coeur d'Alene, Idaho.
31.
"Does Theophylline Still Have a Role in Asthma Management?"
Presentation May 1, 1996, for regional physicians in Great Falls, Montana.
32.
"Diagnosis and Management of Asthma."
Presentation May 18, 1996, for Washington State Society of Medical
Assistants annual meeting, Spokane, Washington.
33.
"Management Guidelines for Allergic Rhinitis."
Presentation June 7, 1996, for Snake River Forum annual meeting in
Lewiston, Idaho.
34.
"Delivery Devices and Oral Inhaled Corticosteroids: Clinical Update in Asthma
Management."
Teleconference presentations to physicians and staff June 19, 26, July
3, 10, 17, September 11, and December 12, 18, 1996.
35.
"Snifflin', Sneezin', and Scratchin'"
Presentation September 3, 1996, for Spokane Valley Hospital physicians,
Spokane, Washington.
Richard G. Gower, M.D.
16
36.
"Winter Asthma and Allergy"
Presentation October 10, 1996, for community physicians in Spokane, Wa.
37.
"Advancements in Asthma Treatments: Newer Corticosteroids and Delivery Systems."
Presentation November 6, 1996, for community pulmonologists in Spokane,
Washington.
38.
"The Socioeconomic Impact of Allergic Rhinitis/Sinusitis"
Presentation December 10, 1996 for regional nurse practitioners in Spokane,
Washington.
39.
"Medical Implications of Urticaria/Angioedema"
Presentation December 23, 1996, for University of Washington housestaff
and community physicians in Spokane, Washington.
40.
“Allergic Rhinitis: It’s Clinical and Economic Impact”
Presentation March 4, 1997, for regional physicians in Walla Walla, Wa.,
and Yakima, Wa.
41.
“The Changing Role of Anti-Inflammatory Therapy in Asthma”
Presentation March 22, 1997, for community physicians in Seattle, Wa.
42.
“Asthma Overview and Treatment Guidelines”
Presentation March 27, 1997, for community physicians in Spokane, Wa.
43.
“The Association of Allergic Rhinitis and Sinusitis”
Presentation April 3, 1997, for regional physicians in Kennewick, Wa.
44.
“The Role of Leukotriene Modifiers in the Treatment of Asthma”
Presentation April 15, 1997, for regional physicians in Walla Walla, Wa.
Presentation December 6, 2001, for regional physicians in Kennewick, Wa.
45.
“New Therapies and Delivery Systems for Asthma”
Presentation April 24, 1997, for regional physicians in Spokane, Wa.
46.
“Breathe Easy: Asthma Update”
Healthtalks Community Education Seminar, May 14, 1997, Spokane, Wa.
47.
“Physical, Social, and Economic Impact of Allergic Rhinitis”
Presentation May 28, 1997, for regional physicians in Coeur d’Alene, Id.
48.
“ New Guidelines for the Diagnosis and Management of Asthma”
Presentation August 24, 1997, for regional physicians in Portland,
Oregon
Richard G. Gower, M.D.
17
49.
“The Association of Allergic Rhinitis, Asthma, and COPD”
Presentation August 27, 1997, for local physicians in Spokane, Wa.
50.
“The Allergy-Asthma Link”
Presentation September 4, 1997, for regional physicians in Boise, Id.
Presentation March 18, 1999, for regional physicians in St. Maries, Id.
Presentation April 16, 1999, for Lovelace Clinic Grand Rounds,
Albuquerque, New Mexico.
“Significance and Treatment of Allergic Rhinitis”
Teleconference presentation on September 25, 1997, for regional physicians
51.
52.
“Immunologic Tests in Allergy/Asthma/Immunology”
Presentation September 26, 1997, at Washington State Medical Association
in Yakima, Wa.
53.
“Allergy Awareness in the Pediatric Population”
Presentation October 15, 1997, for regional pharmacists in Pullman, Wa.
54.
“Treating Asthma in a Managed Care Environment”
Presentation November 15, 1997, for regional physicians at Regional Consultants’
Meeting on Asthma in Snoqualmie, Wa. Moderator of meeting.
55.
“Oral Inhaled Corticosteriod Therapy as the Cornerstone of Treatment in Persistent
Asthma”
Teleconference presentations to western regional physicians October 8, 21, 23,
28, 1997 and November 4, 20, 1997.
56.
“The Role of Leukotriene Modifiers in the Treatment of Asthma”
Presentation November 21, 1997 for regional physicians in Yakima, Wa.
Presentation December 4, 1997, for regional physicians in Pasco, Wa.
57.
“Setting Sights on New Asthma Therapies and Delivery Systems”
Presentation December 6, 1997, for local physicians in Spokane, Wa.
58.
“Resistance in Respiratory Tract Infections”
Presentation December 10, 1997, for local physicians in Spokane, Wa.
59.
“Antiviral Update”
Presentation December 15, 1997, for local physicians in Spokane, Wa.
60.
“Update in Allergic Rhinitis”
Presentation December 16, 1997, for regional physicians in Spokane, Wa.
61.
“Update on Allergic Rhinitis and Inhaled Steroids”
Presentation December 20, 1997, for regional physicians in Seattle, Wa.
Richard G. Gower, M.D.
18
62.
“Asthma/Allergy Link”
Presentation January 16, 1998 for regional physicians in Honolulu, Hi.
Presentation October 22, 1998 for regional physicians in Anchorage, AK.
Presentation December 14, 2005, for regional physicians in Portland, Or.
63.
“Oral Corticosteroids in the Treatment of Asthma”
Presentation January 28, 1998 to regional pharmacists in Coeur d’Alene, Id.
64.
“New Asthma Therapies (Leukotrienes): Effectively Control Your Patients With
Asthma”
Presentation March 17, 1998 to Northwest Academy of Family Practice
Annual Meeting in Spokane, Washington
65.
“Inhaled Bronchial Steriods: Delivery, Proof in 3-D”
Presentation March 22, 1998 to regional physicians in Spokane, Wa.
66.
“The Role of Leukotriene Inhibitors in the Management of Asthma”
Presentation April 15, 1998 for regional physicians’ Grand Rounds
in Lewiston, Idaho
67.
“What’s New in the Treatment of Allergic Rhinitis”
Presentation May 5, 1998, to regional physicians, Great Falls, Mt.
68.
“Children and Asthma”
Presentation May 6, 1998 for Community Health Education and
Resources Meeting, Spokane, Washington
69.
“Management of Allergic Rhinitis”
Presentation July 15, 1998, to regional physicians in Coeur d’Alene, Id.
Presentation June 2, 2001, to regional physicians in Seattle, Wa.
Presentation May 18, 2005, to regional physicians in Coeur d’ Alene, Id.
70.
“Cornerstones of Asthma Treatment (New NIH Guidelines)”
Presentation September 26, 1998, at the Northwest Society of Allergy
Nurses’ Annual Conference, Otter Bay, Oregon
71.
“Allergic Rhinitis”
Presentation October 23, 1998, at Alaska Regional Grand Rounds,
Anchorage, Alaska
72.
“Managing Adult Asthma: A Dialogue on Current Issues and Options”
Presentation April 30, 1999, to regional physicians at the Primary
Care Update 16th Annual Conference, Spokane, Washington
Richard G. Gower, M.D.
19
73.
“Managing Asthma and Issues in Drug Delivery”
Presentation May 6, 1999 to regional physicians in Missoula, Montana
Presentation August 8, 1999, to regional physicians in Seattle, Wash.
Presentation August 10, 1999 to regional physicians in Pasco, Wash.
Presentation August 14, 1999 to regional physicians in Seattle, Wash.
Presentation September 18, 1999, to regional physicians in Seattle, Wash.
Presentation December 11, 1999, to regional physicians in Sandpoint, Idaho
74.
“Treatment of Allergic Rhinitis and Sinusitis in the 90’s”
Presentation July 20, 1999, to regional physicians in Carlsbad, California
75.
“Efficacy of Mometasone Furoate in Patients with Mild to Moderate Asthma:
Once-Daily vs. Twice-Daily Dosing”
Presentation August 28, 1999 to national mometasone furoate investigors’
meeting, San Francisco, California
76.
“Allergic Rhinitis”
Presentation September 15, 1999, to regional physicians in Post Falls, Id.
77.
“The Role of Leukotriene Antagonists in Asthma Management”
Presentation September 16, 1999, Lewiston, Idaho.
Presentation September 17, 1999 Coeur d’Alene, Idaho
Presentation April 19, 2001, Lewiston, Idaho
Presentation June 19, 2001, Boise, Idaho
Presentation June 12, 2002, Lewiston, Idaho
Presentation November 8, 2002, Hermiston, Oregon
Presentation December 10, 2002, Yakima, Washington
78.
Mometasone Faculty Consensus Speaker’s Bureau:
“Grand Rounds in Asthma Management”, presentations October 23, 24, 1999 at
national meeting in Vancouver, British Columbia.
“Asthma Tutorial Workshops”, panelist/moderator, October 30, 31, 1999 at
national meeting in Scottsdale, Arizona
79.
“Treatment Options in Rhinosinusitis”
Presentation February 18, 2000, to regional physicians in San Diego, Ca
Presentation March 4, 2000, to regional physicians in Sandpoint, Id.
Presentation March 22, 2000, to regional physicans in Richland, Wa.
Presentation April 19, 2000, to regional pharmacists in Pullman, Wa.
Presentation April 20, 2000, to regional physicians in Avondale, Id.
Presentation July 15, 2000, to regional physicians in Kellogg, Id.
Presentation February 23, 2001, to regional physicians in Great Falls, Mt.
Presentation June 7, 2001, at the 24th Annual Snake River Medical Forum,
Lewiston, Idaho
.
Richard G. Gower, M.D.
20
80.
“Delivery Systems in the Treatment of Asthma”, ,
Presentation April 12, 2000, to regional physicians in Lewiston, Id.
81.
“Oral Inhaled Corticosteroids in the Treatment of Asthma”
Presentation May 9, 2000, to regional physicians in Coeur d’Alene, Id.
82.
“CDC Guidelines for Treatment of Respiratory Infections”
Presentation December 20, 2000, to regional physicians in Coeur d’Alene, Id.
83.
“The Role of Combination Therapy in the Treatment of Asthma”
Presentation February 6, 2001, Lewiston, Idaho
Presentation February 28, 2001, Pullman, Washington
Presentation April 17, 2001, Lewiston, Idaho
Presentation July 26, 2001, Tacoma, Washington
Presentation March 16, 2002 at Alaska Academy of Family Physicians Annual
Conference, Anchorage, Alaska
Presentation March 29, 2002, Moscow, Idaho
84.
“Does Early Treatment Reduce Morbidity and Mortality in Asthma?”
Presentation June 7, 2001, at the 24th Annual Snake River Medical Forum,
Lewiston, Idaho
85.
“Anti-IgE Therapy: A Novel Treatment for Asthma”
Presentation May 17, 2004, Butte, Montana
Presentation May 12, 2004, Moses Lake, Washington
Presentation April 15, 2004, Lewiston, Idaho
Presentation October 7, 2001, Northwest Society of Allergy Nurses’ 14th
Educational Conference, Newport, Oregon
Presentation August 20, 2003, Tacoma, Washington
Presentation September 11, 2003, Airway Heights, Washington
Presentation September 23, 2003, Kennewick, Washington
Presentation September 25, 2003, Spokane, Washington
Presentation October 22, 2003, Billings, Montana
Presentation December 4, 2003, Walla Walla, Washington
Presentations February 23, 2004, Great Falls and Helena, Montana
Presentation March 31, 2005, Kellogg, Idaho
Presentation May 12, 2005, St. Maries, Idaho
Presentation July 11, 2005, Everett, Washington
Presentation December 7, 2005, Trinidad, California
86.
“Anaphylaxis”
Presentation October 16, 2001, to regional physicians in Steilacomb, Wa.
87.
“The Role of Long-Acting Beta 2 Agonists in Asthma Management”
Presentation October 24, 2001, to local physicians in Richland, Wa.
Richard G. Gower, M.D.
21
88.
“Allergic Rhinitis”
Presentation November 15,2001, to national investigator’s meeting in
Orlando, Florida—ACAAI physician survey.
89.
“The Social and Physiologic Effects of Allergic Rhinitis”
Presentation February 23, 2002, Sandpoint, Idaho
Presentation April 13, 2002, Renton, Washington
Presentation April 24, 2002, Seattle, Washington
Presentation May 3, 2002, Sheridan, Wyoming
Presentation May 22, 2002, Seattle, Washington
Presentation May 29, 2002, Coeur d’Alene, Idaho
Presentation June 29, 2002, Anchorage, Alaska
Presentation December 11, 2002, Mountain Home, Idaho
90.
“Patient Preference in Allergic Rhinitis”
Presentation March 23, 2002, to National Respiratory
Visiting Professor Program, Lake Louse, Alberta, Canada
National Teleconference Speaker: March 4, 5, 6, 12, 13, 18, 19, 20, 21, 25, 26
April 1, 3, 11, 17, 22, 23, 29; September 23, 24; October 1, 3, 24, 2002
91.
“How to Differentiate Sinus from Migraine Headaches”
Presentation May 14, 2002, Seattle, Washington
Presentation May 21, 2002, Portland, Oregon
Presentation June 5, 2002, Seattle, Washington
Presentation July 16, 2002, Portland, Oregon
Presentation July 18, 2002, Salt Lake City, Utah
92.
Co-Chair, Respiratory Speaker Academy Training Program,
December 13-15, 2002, Orlando, Florida
93.
“The Role of Leukotriene Inhibitors in the Treatment of Allergic Rhinitis”
Presentation May 5, 2004, Richland, Washington
Presentation April 20, 2004, Lewiston, Idaho
Presentation April 19, 2004, Great Falls, Montana
Presentation April 13, 2004, Olympia, Washington
Presentation May 29, 2003, Richland, Washington
Presentation May 15, 2003, Kirkland, Washington
Presentation April 17, 2003, Modesto, California
Presentation April 16, 2003, Kennewick, Washington
Presentation March 26, 2003, Lewistown, Montana
Presentation March 25, 2003, Lewiston, Idaho
Presentation March 18, 2003, Hillsboro, Oregon
Presentation March 10, 2003, Moses Lake, Washington
Presentation March 4, 2003, Great Falls, Montana
Presentation February 26, 2003, Chelan, Washington
Presentation February 6, 2003, Portland, Oregon
Richard G. Gower, M.D.
22
94.
“An Update of the Treatment of Allergic Rhinitis”
Presentation (RCM) May 8, 2004, Cleveland, Ohio
Presentation February 27, 2003, Deer Park, Washington
Presentation March 19, 2003, Cheney, Washington
Presentation May 14, 2003, Portland, Oregon
Presentation May 20, 2003, Richland, Washington
National Teleconference Speaker: January 15, 30; February 12, 19;
March 5, 11, 12, 20, 24, 27; April 23, 30; May 7, 13, 2003
95.
“Reactions to Remicaide”
Presentation May 5, 2003, Spokane, Washington
96.
“How Should We Be Using Antibiotics? Resistance Issues”
Presentation at Primary Care Physicians’ Twentieth Annual Conference,
May 3, 2003, Spokane, Washington
97.
“An Update on Allegra for Allergic Rhinitis”
Presentation March 1, 2003, Phoenix, Arizona
Presentation April 26, 2003, Pittsburgh, Pennsylvania
Presentation July 12, 2003, Travis, Michigan
98.
“Ciclesonide: A Novel Oral Inhaled Corticosteriod for the Treatment of Asthma”
Presentation March 1, 2003, Phoenix, Arizona
Presentation April 26, 2003, Pittsburgh, Pennsylvania
Presentation July 12, 2003, Travis, Michigan
99.
“The Role of Isomers in the Treatment of Asthma”
Presentation September 12, 2003, Coeur d’Alene, Idaho
100.
“Allergic Rhinitis and Urticaria: Case Presentations”
Presentation September 18, 2003, Lewiston, Idaho
101.
“The Association of Allergic Rhinitis and Asthma: Chronic Allergic Respiratory
Syndrome”
Plenary Session Presentation at the Third Balkan Congress of Allergy and
Clinical Immunology on October 13, 2003, Istanbul, Turkey
102.
“The Role of Small Airways in Asthma Management”
Presentation May 25, 2004, Reno, Nevada
Presentation May 18, 2004, Benton County Medical Society, Pasco, Washington
Presentation February 4, 2004, Yakima, Washington
103.
“Chronic Allergic Respiratory Syndrome”
Presentation March 16, 2004, Medical Grand Rounds,
Walla Walla, Washington
Richard G. Gower, M.D.
23
104,
“The Role of Leukotriene Modifiers in the Treatment of Allergic Rhinitis and Asthma”
Presentation October 19, 2004, Honolulu, Hawaii
Presentation September 22, 2004, Eugene, Oregon
Presentation September 9, 2004, Newport, Washington
Presentation September 8, 2004, Great Falls, Montana
Presentation September 1, 2004, Tacoma, Washington
Presentation July 22, 2004, Silverdale, Washington
Presentation May 19, 2004, to University of Washington medical residents, Seattle, Wash
Presentation May 13, 2004, Portland, Oregon
Presentation February 7, 2005, Yakima, Washington
Presentation March 24, 2005, Yakima, Washington
Presentation March 29, 2005, Federal Way, Washington
105.
“New Treatments in the Management of Asthma”
Presentation October 2, 2004 in Spokane, Washington at the Washington State Medical
Association Annual Meeting
Presentation May 21, 2004 in Wenatchee, Washington at the Washington Academy of
Family Practice
106.
“Allergic Rhinosinusitis”
Presentation September 21, 2004, at Medical Grand Rounds, Kennewick, Washington
Presentation August 26, 2004, Moscow, Idaho
Presentation June 4, 2004 in Sandpoint, Idaho
107.
“Hymenoptera Hypersensitivity”
Plenary talk at Polish Allergy Society Meeting in Krakow, Poland on August 1, 2004
108.
“Management of Respiratory Infections”
Presentations November 3, 2004, Odessa and Yakima, Washington
Presentation January 18, 2005, Whitefish, Montana
Presentation January 19, 2005, Medical Grand Rounds, Missoula, Mt.
Presentation April 20, 2005, Portland, Oregon
Presentations April 21, 2005, Billings, Mt. and Sheridan, Wyoming
Presentations July 19, 20, 2005, Helena, Montana
Presentations September 14, 2005, Moses Lake and Yakima, Wa.
Presentations October 13, 2005, Billings, Mt. and Sheridan, Wyoming
Presentation October 27, 2005, Richland, Washington
Presentation November 16, 2005, Coeur d’Alene, Idaho
Presentation December 20, 2005, Medical Grand Rounds, Kennewick, Wa.
109.
“Allergies, Asthma, and Allergy Testing”.
Presentation April 14, 2005, Annual Meeting of American College of
Physicians, San Francisco, California
110.
“Allergic Rhinitis: Looking Beyond Quality of Life”.
Presentation April 30, 2005, Portland, Oregon
Presentation June 3, 2005, Milwaukee, Wisconsin
Richard G. Gower, M.D.
24
111.
“Mechanisms of Allergy and Asthma”.
Presentation September 10, 2005, Annual Meeting of Northwest
Society of Allergy Nurses, Gleneden Beach, Oregon
112.
“Allergies, Asthma, and Allergy Testing"
Presentation June 6, 2006; 16th International Meeting of Asthma, Allergy,
and Immunology, Buenos Aires, Argentina.
113.
“Association of Allergic Rhinitis and Asthma: Chronic Allergic Respiratory
Syndrome”.
Presentation June 6, 2006; 16th International Meeting of Asthma, Allergy,
and Immunology, Buenos Aires, Argentina.
114.
“Hymenoptera Hypersensitivity”
Presentation October 29, 2007; 34th Brazil Congress of Allergy and
Immunopathology, Salvador, Brazil.
115.
“Will Pay for Performance Improve Allergy and Asthma Care?”
Presentation November 13, 2007; American College of Allergy, Asthma, and
Immunology, Dallas, Texas
116.
“Anaphylaxis”
Presentations December 9 and 11, 2007; Annual Meeting of Hong Kong Allergy
Convention, Hong Kong and Xian, China
117.
“Angioedema and Urticaria”
Presentations December 9 and 11, 2007; Annual Meeting of Hong Kong Allergy
Convention, Hong Kong and Xian, China
118.
“Rhinitis Practice Parameter Update”
Presentation December 5, 2008; Jerusalem, Israel
119.
“State of the College”
Presentation December 6, 2008; Jerusalem, Israel
March, 2009; Dubai
August 2009, Ecuador
September 2009, Georgia
November 2009; Miami, FL
120.
“Improving the Quality of Life in patients with Severe Persistent Asthma”
Presentation March, 2009; Dubai
August 2009, Ecuador
September 2009, Georgia
November 2009; Miami, FL
Richard G. Gower, M.D.
25
121.
“Improving Outcomes in Hereditary Angioedema Clinical Cases and Expert Opinion:
Individualization of Therapy” Presentation, November 2010, Phoenix, AZ
PHARMACEUTICAL STUDIES:
1.
Asthma Study (Tilade, Fisons), Primary Investigator, summer 1993.
2.
Allergic Rhinitis Study (Rhinocort, Astra), Primary Investigator,
summer 1994.
3.
Asthma Study (Serevent, Glaxo 5001), Primary Investigator,
1994-1995.
4.
Sinusitis Study (Vantin, Upjohn), Primary Investigator,
1995-1997.
5.
Asthma Study (MK-0476, Merck), Subinvestigator, 1994-1995.
6.
Herpes Zoster Study (Famciclovir, Smith, Kline, Beecham),
Primary Investigator, 1995.
7.
Asthma Study (Vanceril, Schering/Key), Primary Investigator,
spring 1995.
8.
Asthma Study (Powdered Salmeterol, Diskus, Glaxo 3011), Primary Investigator,
1995-1996.
9.
Asthma Study (Intal, Fisons Corporation), Sub-investigator, 1995-1996.
10.
Asthma Study (Pranlukast, Anti-leukotriene, SmithKline Beecham), Primary
Investigator, 1995-1996.
11.
Asthma Study (Azmacort HFA-134a non-CFC propellant study, Rhone-Poulenc
Rorer), Primary Investigator, 1995-1996.
12.
Asthma Study (Sepracor 051-024, R-Albuterol in the Reversal of Bronchoconstriction and in the Management of Asthma, Phase III), Primary Investigator,
1996-1997.
13.
Skin Testing (Evaluation of English Plantain Proposed Reference using the
SARAH Method, AF-95-001, Bayer Corporation), Primary Investigator,
1996.
Richard G. Gower, M.D.
26
14.
Asthma Study, C96-137 (Placebo-Controlled Efficacy and Safety Study with
Long-Term Safety Evaluation of Mometasone Furoate Dry Powder in
Reducing Oral Steroid Requirements in Patients with Severe Asthma; ScheringPlough, Phase III), Primary Investigator, 1996-1998.
15.
Bronchitis Study (Acute Exacerbation of Chronic Bronchitis, Bay 12-8039,
Phase II, Bayer Corporation), Primary Investigator, 1996-1997.
16.
Sinusitis Study (Acute Bacterial Maxillary Sinusitis, Bay 12-8039/Protocol
#D96-023, Phase II, Bayer Corporation), Primary Investigator, 1996-1999.
17.
Bronchitis Study (Acute Bronchitis, M96-456, Phase III, Abbott Pharmaceuticals),
Primary Investigator, 1997.
18.
Asthma Study (Pranlukast, Phase III, SkB, SB205312), Primary Investigator,
1996-97.
19.
Asthma Study (Schering-Plough C-96-196, Phase III), Primary Investigator,
1997-1998.
20.
COPD Study (SLGA-4021: A Comparison of Salmeterol Versus Theophylline
versus Salmeterol Plus Theophylline in COPD Patients), Glaxo Wellcome, Inc.,
1997-1998.
21.
Asthma Study (Spokane Epidemiologic Survey of Asthma, University of
Washington School of Medicine), Coinvestigator, 1997-1998.
22.
Asthma Study (Schering-Plough C97-223, Phase III), Primary Investigator,
1997-1998.
23.
Asthma Study (Schering-Plough C97-224, Phase III), Primary Investigator,
1997-1998.
24.
Asthma Study (Zeneca Study No. 91 88IL/0150:0020, Phase III),
“A Multicenter Double-Blind Comparison of Zafirlukast With Placebo in
Pediatric Subjects with Mild-to-Moderate Asthma”, Primary Investigator,
1997-1998.
25.
Chronic Bronchitis Study (Abbott, Phase III, M97-766), Primary Investigator,
1997-1998.
26.
Asthma Study (Schering-Plough C-98-005-09, Pediatric, Phase III), Primary
Investigator, 1998-1999. “Placebo Controlled Efficacy and Safety Study of
Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of
Asthma in Children Previously Maintained on Inhaled Corticosteroids”
Richard G. Gower, M.D.
27
27.
28.
Asthma Study (Sepracor, Xopenex Solution, Phase IV), Primary Investigator,
1998-1999.
Reversible Obstructive Airways Disease Study (Novartis CGP25827A/073,
Formoterol, Phase III), Primary Investigator, 1998-1999. “Randomized
Parallel Group Open Label Multicentered Clinical Study Comparing the Safety,
Efficacy, Quality of Life, and Socioeconomic Variables of Twice Daily Formoterol
Powder (12 micrograms bid) to Twice Daily Salmeterol (50 micrograms bid)
Administered for Six Months to Adult Subjects with ROAD”
29.
COPD Study (SmithKline Beecham, Ariflo, SB207499/039, Phase IIIA),
Primary Investigator, 1998-1999. “A 24-Week Double Blind Placebo Controlled
Randomized Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability
of Oral Ariflo (15 mg bid) in Patients with COPD”
30.
COPD Study (Glaxo FLTA3025, Phase III) Primary Investigator, 1998-1999.
“A Randomized Double-Blind Parallel-Group Comparative Trial of Inhaled
Fluticasone Proprionate Via the Diskus...in Patients with COPD”
31.
Allergic Rhinitis/Seasonal Asthma Study (Schering-Plough P97-293, Phase IV),
Primary Investigator, 1998-1999.
32.
Asthma Study, Named Patient (Astra, Pulmicort Respules, Study #04-3121,
Phase IV), Primary Investigator, 1998-1999.
33.
Asthma Study, (SKB, CPMS Protocol: SB2445063-006, Phase IIA, IL-5),
Primary Investigator, 1998-1999. “A Multicenter, Double-Blind, Placebo-,
Controlled Randomized Study to Evaluate the Safety and Efficacy of SB240563 in
Patients with Moderate Asthma”
34.
Asthma Study, (Glaxo Wellcome, SAS40021: Phase IV), Primary Investigator,
1999-2000. “A Randomized, Double-Blind, Double-Dummy, Parallel Group,
12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination
Product 50/100mcg BID Via the DISKUS Inhaler Versus Oral Montelukast
10mg QD in Adolescents and Adults with Persistent Asthma”
35.
Influenza Study in Asthma and COPD, (Glaxo Wellcome, NAI30008), Primary
Investigator, 1999-2000. “A Double-Blind, Randomized, Placebo-Controlled,
Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of
Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the
Treatment of Influenza in Patients 12 Years or Over Diagnosed with Asthma
or Chronic Obstructive Pulmonary Disease”
36.
Seasonal Allergic Rhinitis Study (Schering-Plough Pol376-32). Primary
Investigator, summer/fall 2000. “Efficacy and Safety of Desloratadine 5 mg
Tablet in the Treatment of Subjects 12-17 Years of Age with Seasonal Allergic
Rhinitis”
Richard G. Gower, M.D.
28
37.
Asthma Study (GlaxoSmithKline, FAP 30007, Phase III). Primary
Investigator, 2000-2001. “A Randomized, Double-Blind, Parallel
Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone
Propionate 88 mcg BID, 220 mcg BID, and 440 mcg BID versus
Placebo in Propellant GR 1066 42 X in Adolescent and Adult
Subjects with Asthma who are Maintained on Inhaled Corticosteriod
Therapy”
38.
Asthma Study (GlaxoSmithKline FAP 30008, Phase III). Primary
Investigator, 2000-2001. “A Randomized Double-Blind, Parallel-Group,
Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88 mcg
BID, 220 mcg BID and 440 mcg BID versus Placebo in Propellant GR
106642 X in Adolescent and Adult Subjects with Asthma who are Maintained
on Bronchodilator Therapy”
39.
COPD Study (GlaxoSmithKline SMS40315, Phases III), Primary
Investigator, 2000-2001. “A Multi-Center, Randomized, Double-Blind,
Double-Dummy, Parallel Group, 8 Week Comparison of Salmeterol
Xinafoate Versus Salmeterol Xinafoate plus Ipratropium Bromide Versus
Placebo in Subjects with COPD”
40.
Sinusitis Study (Abbott, ABT-773, Protocol MOO-225, Phase III). Primary
Investigator, 2000-2001. “Comparative Study of the Safety and Efficacy of
ABT-773 150 mg. QD versus 150 mg. BID for the Treatment of Acute
Bacterial Sinusitis”
41.
Asthma Study, Pediatric (Aventis XRP1526B-341, Phase III). Primary
Investigator, 2001. “Double-Blind, Placebo-Controlled, Parallel-Group,
Multicenter, Efficacy, Safety and Dose Response Study of Ciclesonide Metered
Dose Inhaler 50 mcg/day, 100 mcg/day, and 200 mcg/day (Ex-Valve) Administered
Once Daily for 12 Weeks in the Treatment of Children with Persistent Asthma”
42.
Asthma Study, Pediatric (Aventis XRP1526B-341 LT, Phase III). Primary
Investigator, 2001. “A Multicenter, Open-Label, One Year Long Term Safety
Study of Ciclesonide Metered Dose Inhaler 50 mcg/day to 200 mcg/day (ex-valve)
Administered once daily for the Treatment of Children with Persistent Asthma”
43.
Asthma Study, Adolescents and Adults (Aventis 251526-321, Phase III). Primary
Investigator, 2001. “Double-Blind, Placebo-controlled, Parallel-group, Multicenter
Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler
100 mcg/day, 200 mcg/day, and 400 mcg/day (ex-valve) Administered Once Daily
for 12-Weeks in the Treatment of Mild to Moderate Persistent Asthma in
Adolescents and Adults”
Richard G. Gower, M.D.
29
44.
Asthma Study (Aventis XRP1526B-326, Phase III). Primary Investigator,
December 2001. “A Multicenter, Open-label, Long-Term (1 year) Safety Study of
Ciclesonide 100 micrograms/day to 400 micrograms/day (Ex-Valve) Metered Dose
Inhaler Administered Once Daily For the Treatment of Mild to Moderate Persistent
Asthma in Adolescents and Adults.
45.
COPD Study (GlaxoSmithKline, SCO30003, TORCH). Primary Investigator,
2001-2004. “A Multicentre, Randomized, Double-Blind, Parallel Group, PlaceboControlled Study to Investigate the Long-Term Effects of Salmeterol/Fluticasone
Propionate (Seretide/Viani/Advair) 50/500 mcg bd, Salmeterol 50 mcg bd and
Fluticasone Propionate 500 mcg bd, all Delivered Via the Diskus/Accuhaler
Inhaler, on the Survival of Subjects with COPD over 3 years of Treatment”
46.
COPD Study (SmithKline Beecham, SB207499-168, Phase III). Subinvestigator,
2001-2002. “A Randomized, 12-week, Double-blind, Placebo-controlled,
Parallel-group Study to Evaluate the Safety and Tolerability of Ariflo (15 mg bid) in
Patients with Chronic Obstructive Pulmonary Disease (COPD).”
47.
Asthma Study (Genentech, Q2143g, Phase III). Primary Investigator, 2001-2002.
“A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety
of Xolair in Moderate to Severe Persistent Asthma Subjects Already Treated With
Other Therapies (ALTO)”
48.
Rhinitis Study (Merck, PAR 246). Primary Investigator, 2001-2002.
“A Multicenter, Double-Blind, Randomized, Placebo-Controlled, ParallelGroup Study Investigating the Clinical Effects of Montelukast in Patients
With Perennial Allergic Rhinitis (Protocol 246-00)”
49.
Asthma Study (GlaxoSmithKline, SAS40036). Primary Investigator, 2001-2002.
“A Multi-center, Randomized, Double-Blind, Double-Dummy, Parallel Group,
16-Week Comparison of Asthma Control in Adolescents and Adults Receiving
Either Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50
mcg BID, Fluticasone Propionate DISKUS 100 mcg BID, Salmeterol Xinafoate
DISKUS 50mcg BID, or Oral Montelukast 10MG QD”
50.
Asthma Study (Novartis, CFOR258D2307, Phase III). Primary Investigator. 2002.
“A randomized, multicenter, placebo-controlled parallel group study of four
month’s duration per patient to evaluate the safety and efficacy of treatment with
24mcg b.i.d. and 12mcg b.i.d. formoterol, double-blind, and 12mcg b.i.d.
formoterol with additional on-demand formoterol doses, open-label, in adolescent
and adult patients with persistent stable asthma”
51.
Asthma Study (Astra-Zeneca, SD-039-0726, Phase III). Primary Investigator, 2003-2004.
“A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo- and ActiveControlled Study of SYMBICORT pMDI Administered Once Daily in Adults and
Adolescents with Asthma – STEM”
Richard G. Gower, M.D.
30
52.
Asthma Study (Sepracor, Protocol 051-355, Phase III). Primary Investigator, 2003.
“A Double-Blind, Randomized, Placebo- and Active-Controlled, Multicenter,
Parallel-Group Study Evaluating the Safety and Efficacy of 90 micrograms
Levalbuterol, 180 micrograms Racemic Albuterol and Placebo”
53.
Asthma Study (Hoffmann-LaRoche, Protocol BA16631, Phase II). Primary Investigator,
2003-2004. “Dose-ranging Study of Ro 27-2441 in Patients With Persistent Asthma Not
Treated
With Inhaled Corticosteroids”
54.
Asthma Study (Pharmacia/Pfizer, Protocol PDEAAS 1500-002, Phase III),. Primary
Investigator, 2003-2004. “A 24 Week, Double-Blind, Randomized, Placebo –Controlled
Clinical Trial to
Evaluate the Efficacy and Safety of Oral Roflumilast (250mcg or 500mcg) Daily in
Patients with Asthma”
55.
COPD Study (Pharmacia, Protocol PDEACO-9287-001, Phase III). Primary Investigator,
2003-2004. “A 24-Week, Placebo-Controlled, Randomized, Parallel Group Study
Comparing Roflumilast 500 mcg Daily vs. Placebo on Pulmonary Function and
Respiratory Symptoms in Patients with Chronic Obstructive Pulmonary Disease”
56.
Asthma Study (Aventis, Protocol XRP1526B-3027, Phase III). Primary Investigator,
2004-2005. “A Multi-Center, Multinational, Randomized, Double-Blind, Parallel Group
Study of the Effects of Ciclesonide HFA-MDI 640 mcg/Day and Beclomethasone HFAMDI 640 mcg/Day on Lens Opacification in Adult Subjects with Moderate to Severe
Persistent Asthma”
57.
COPD Study (GSK, Protocol SCO40041, Phase III), Primary Investigator, 2004-2007.
“A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of
the Fluticasone Propionate/Salmeterol Combination Product 250/50 mcg BID via
DISKUS versus Salmeterol 50 mcg BID via DISKUS on Bone Mineral Density in
Subjects with Chronic Obstructive Pulmonary Disease (COPD).
58.
Perennial Allergic Rhinitis Study (Altana, Protocol BY9010/M1-403, Phase III).
Primary Investigator, 2005. “A Randomized, Double-Blind, Placebo-Controlled,
Parallel-Group Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of
Ciclesonide Applied As a Nasal Spray at Three Dose Levels (200mcg, 100 mcg, or 25
,mcg once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11
Years of Age”
59.
Sinusitis Study (Bayer, Protocol 100569, Phase IV). Primary Investigator 2004-2005.
“Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial
eradication and key Symptom Relief in the treatment of Acute Bacterial Maxillary
Sinusitis with Moxifloxacin 400 mg QD”
Richard G. Gower, M.D.
31
60.
COPD Study (GSK, Protocol SCO40043, Phase 3), Primary Investigator, 2004-2005.
“A Randomized, Double-Blind, Parallel-Grpi 52-week Study to Compare the Effect
of the Fluticasone Propionate/Salmeterol DISKUSTM Combination Product 250/50mcg
BID with Salmeterol DISKUS 50 mcg BID on the Annual Rate of Moderate/Severe
Exacerbations in Subjects with Chronic obstructive Pulmonary Disease (COPD)”
61.
Chronic Bronchitis Study (Aventis, Protocol HMR 3647A/4020, Phase IV), 2004-2005.
“An open-label, randomized, multi-center, clinical study to compare the effects of
telithromycin, azithromycin and cefuroxime axetil on the penicillin or macrolide
resistance of Streptococcus pneumoniac in patients with acute exacerbation of
chronic bronchitis”
62.
Seasonal Allergic Rhinitis Study (Alcon, Protocol C-04-20, Phase 3), Primary
Investigator, 2005. “Safety and Efficacy of Olopatadine Hydrochloride Nasal
Spray in Pediatric Patients”
63.
Extract Injection Study (Hollister-Stier, HS-JT-OO-OO1A). Primary Investigator,
September 2000. “Comparison of the J-Tip Needleless Syringe to a Conventional
Syringe in the Administration of Allergic Extract”
64.
Antigen Study (Hollister Stier, HS-AP-OO-OO1A). Primary Investigator, October
2000. “Quantitative Intradermal Procedure to Determine Relative Potency and
Compositional Differences Between AP(R) Dog and Regular Process Dog
Allergenic Extracts”
65.
Antigen Study (Hollister Stier, Protocol HS-AG-OO-OO1R). Primary Investigator
November 2000 “Quantitative Procedure to Determine Relative Potency and
Compositional Differences Between Diafiltered Short Ragweed
Allergenic Extract
and Two Commercially Available Short Ragweed Allergenic Extracts”
Asthma Study (GlaxoSmithKline, SLGA 5011), (SMART). Primary Investigator, 2000.
“Salmeterol Multicenter Asthma Research Trial Study”.
66.
67.
Asthma Study (Genentech, Protocol Q2196n), (TENOR). Primary Investigator, 20002003. An Observational Study of the Epidemiology and Natural History of Asthma:
Outcome and Treatment Regimens”.
68.
Asthma Study (Genentech, Protocol Q2948g), (EXCELS). Primary Investigator, 20042009. “An Epidemiological Study of Xolair (Omalizumab): Evaluating Clinical
Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma”.
69.
Asthma Study (Novartis, Protocol #CIGE025AUS23, Phase lV), (CLUSTER). Primary
Investigator, 2006-2007. “A 26 –Week, Randomized, Double-Blind, Parallel-Group,
Placebo Controlled, Multi- Center Study to Evaluate the effect of Xolair on Improving
the tolerability of specific Immuno-Therapy in Patients with at least Moderate Persistent
Allergic Asthma Inadequately Controlled with Inhaled Corticosteroids.”
Richard G. Gower, M.D.
32
70.
Hereditary Angioedema Study (LEV Pharmaceuticals, LEVP2005-1, Phase III). Principal
Investigator, 2006-2007. “C-1 Inhibitor in Hereditary Angioedema Nanofiltration
Generation Evaluating Efficacy Trial”
71.
Allergy Study (Kendle International, GrassMATAMPL301, Phase III). Principal
Investigator, 2007-2007. “Efficacy and Safety/Tolerability of Grass MATA MPL, a
Randomized, Placebo-Controlled, Double-Blind Study”.
72.
Allergic Rhinitis (Sanofi-Aventis, XRG5029C/3503, Phase IIIa). Principal Investigator,
2007-2008. “A Randomized, Multi-center, Double-Blind, Placebo-Controlled, Parallel
Group Study of the 12 Month Effect of Treatment with Once Daily Triamcinolone
Acetonide (NASACORT AQ Nasal Spray 100ug) on the Growth Velocity of Children 3-9
Years of Age, with Perennial Allergic Rhinitis”.
73.
Severe Disease to Assess Asthma Control, Allergies, Patient Outcomes and Treatment
Study. (CHARIOT). Retrospective Chart Review Study 2007
74.
Combivent Study (Boehringer Ingelheim, 1012.56, (Phase 3). Sub Investigator, 2006 –
2008. “A comparison of ipratropium bromide/salbutasmol delivered by the Respimat
inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the
Respimat in a 12 week, double-blind, safety and efficacy study in adults with chronic
obstructive pulmonary disease
75.
Crescendo Study (Sanofi Aventis, SR141716, (Phase 3). Sub Investigator 2005 –
present. “Randomized, multinational, multi-center, double-blind, placebo-controlled,
two-arm parallel group trial of rimonaqabant 20 mg OD for reducing the risk of major
cardiovascular events in abdominally obese patients with clustering risk factors.”
76.
COPD/Inhaled Insulin, (Pfizer, A2171030, phase III). Sub Investigator 2006 – 2007.
“Efficacy and Safety of Inhaled Human Insulin (Exubera). Compared with Subcutaneous
Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus
and Chronic Obstructive Pulmonary Disease. A One-Year Multi center, Randomized
Outpatient, Open-Label, Parallel Group Comparative Trial.”
77.
Asthma/Inhaled Insulin, (Pfizer, A2171028, phase III). Sub Investigator 2006 – 2007.
“Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared with Subcutaneous
Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus
and Chronic Asthma. A One Year Multi-center Randomized, Outpatient, Open-Label,
Parallel-Group Comparative Trial.”
78.
Osteoarthritis/Rheumatoid Arthritis, (Pfizer, A3191172, Phase IV) Sub Investigator
2006 – present. “A Randomized, Double-Blind, Parallel-Group Study of Cardiovascular
Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for
Cardiovascular Disease comparing Celecoxib with Naproxen and Ibuprofen.”
Richard G. Gower, M.D.
33
79.
Pneumonia, (Enanta Pharmaceuticals, Inc., EDP420-05-006, phase IIa), Sub Investigator
2005 – 2006 “A Randomized, Double-Blinded, Parallel Group, Multi-Center study of
EDP-420 versus Telithromycin for the Treatment of Community Acquired Pneumonia.”
80.
Diabetes, (Novartis, CLAF237A23119, Phase 3b), Sub Investigator 2006 – present. “A
multi-center, randomized, open-label, active controlled, parallel arm study to compare the
efficacy of 12 weeks of treatment with Vildagliptin 100 mg, qd to thiazolidinedione
(TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with
metformin monotherapy in a community-based practice setting.”
81.
Insomnia, (Takeda, 01-05-TL-375-069), Sub Investigator 2007 – present. “A
Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Demonstrate
the Subjective Treatment Effects of Ramelteon on Sleep Using a Post Sleep
Questionnaire-Interactive Voice Response System (PSQ-IVRS) in an “At Home Setting”
in an Adult Population with Chronic Insomnia.”
82.
Gout, (TAP Pharmaceutical Products, Inc, F-GT06-153, Phase 3), Sub Investigator
2006 – present. “A Randomized, Multi-Center, Double-Blind, Allopurinol-Controlled
Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects with Gout.”
83.
COPD (Glasko-Smith-Kline, SCO100250, phase ), Sub Investigator, 2007-2008. “A
Randomized, Double-Blind, Parallel-Group, 52-week Study to Compare the Effect of the
Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 bid with
Salmeterol DISKUS 50 mcg bid on the Annual Rate of Moderate/Severe Exacerbations in
Subjects with Chronic Obstructive Pulmonary Disease (COPD).”
84.
Asthma (AstraZeneca, D5896C00025 phase ), Sub Investigator, 2006-2008, “A twoweek, Randomized, Double-Blind Study Assessing the Onset of Effect Questionnaire
(OEQ) Administered Pre-dose Versus Post-dose in Adult Subjects (≥18 years of age)
with Mild to Moderate Asthma, Receiving SYMBICORT pMDI 80/4.5 ug x 2 Actuations
Twice Daily or Budesonide HFA pMDI 80 ug x 2 Actuations Twice Daily.”
85.
Asthma (Genentech Q3662g, EXTRA phase ), Principal Investigator, 2006-2008, “A
Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair
in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled
High-Dose Inhaled Corticosteroids and Long-Acting Beta-Antagonists.”
86.
Asthma (Schering-Plough, P04828), Principal Investigator, 2007-2008, “A Study of the
Therapeutic Equivalency of MF DPI 100 mcg and 200 mcg Inhalers in CorticosteroidDependent Subjects with Moderate Asthma.”
87.
Asthma (Boehringer Ingelheim, 1012.56), Sub Investigator, 2006-2008, “A Comparison
of Ipratropium Bromide / Salbutamol Delivered by the Respimat Inhaler to Combivent
Inhalation Aerosol and Ipratropium Bromide Delivered by the Respimat.”
Richard G. Gower, M.D.
34
88.
Conjunctivitis (Alcon, SMA-07-03, phase IV). After Market Research, 2007. “Pataday
Allergic Conjunctivitis Evaluation )PACE) Trial, a Multi-site, Open-Label Study of
Patient Perception of the Use of Olapatadine 0.2% with Patients who Previously used
Other Ocular Anti-Allergy Medication.”
89.
COPD (Boehringer Ingelheim, 1205.14, phase ) Sub Investigator, 2007-2008. “A MultiNational, Randomized, Double-Blind, Placebo and Activated-Controlled, Parallel Group
Efficacy and Safety Comparison over 24 weeks of Three Doses (50 ug, 100 ug, 200 ug) of
BEA 2180 to Tiotropium 5 ug and Placebo Delivered by the Respimat Inhaler in Patients
with Chronic Obstructive Pulmonary Disease (COPD).”
90.
Pneumonia (Boehringer Ingelheim, 1205.14, phase ) Sub Investigator, 2007-2008. “ A
Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of
Faropenem Medoxomil 600 mg PO, BID for 10 days Versus Levofloxacin in the
Treatment of Community-Acquired Pneumonia.”
91.
Asthma (Glasko-Smith-Kline, FFA109684), Primary Investigator. 2008 “A Randomized,
Double-Blind, Double Dummy, Placebo controlled, Parallel Group, Multicenter Dose
Ranging Study to Evaluate the Efficacy and Safety of Inhalation Powder Once Daily and
Fluticasone Propionate Inhalation Powder 500 mcg Twice Daily Compared with Placebo
for 8 weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on a
Moderate Dose of ICS Therapy.”
92.
Asthma (Glasko-Smith-Kline, FFA109685), Primary Investigator. 2008 “A Randomized,
Double-Blind, Double Dummy, Placebo Controlled, Parallel Group, Multicenter Dose
Ranging Study to Evaluate the Efficacy and Safety of Inhalation Powder Once Daily and
Fluticasone Propionate Inhalation Powder 250 mcg Twice Daily Compared with Placebo
for 8 weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on a
Low Dose of ICS Therapy.”
93.
Asthma(Glasko-Smith-Kline, FFA109687), Primary Investigator. 2008 “A Randomized,
Double-Blind, Double Dummy, Placebo Controlled, Parallel Group, Multicenter Dose
Ranging Study to Evaluate the Efficacy and Safety of Inhalation Powder Once Daily and
Fluticasone Propionate Inhalation Powder 100 mcg Twice Daily Compared with Placebo
for 8 weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on
Non-Steroidal Asthma therapy.”
94.
Ocular Safety. (Glasko-Smith-Kline, FFR110537), Primary Investigator. 2008. “A
Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter, Two-year
Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110
mcg in Adults and Adolescents 12 Years of Age and Older with Perennial Allergic
Rhinitis.”
Richard G. Gower, M.D.
35
95.
Sublingual Immunotherapy (Schering Plough P05239-children, P05238-adults) Primary
Investigator. 2008-2009 “A Double-Blind, Randomized, Placebo-Controlled, ParallelGroup Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy with SCH
697243 (Phleum Pratense) in Adults and Children with a History of Grass Pollen Induces
Rhinoconjunctivitis With or Without Asthma.”
96.
Pneumonia. (Wyeth 6115A1-3000) Primary Investigator. 2009. “A Phase 3, Open-Label,
Single-Arm Trial Evaluating the Safety, Tolerability, and Reactogenicity of a 13-valent
Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults Aged 70 Years and
Older Who Received 1 Dose of 23-valent Pneumococcal Polysaccharide Vaccine at Least
5 Years Before Study Enrollment.”
97.
COPD (Forest LAS-MD-36) Investigator. 2009. “Aclidinium Bromide (muscarinic
antagonist) Inhaler at two Dosage Levels Administered to Patients with Moderate to
Severe COPD.”
98.
COPD (GSK-HZC102871) Investigator. 2009. “52 week Efficacy and Safety Study to
Compare three Dosages of Fluticasone Furoate with a New LABA vs. New LABA Alone
on the Annual Rate of Exacerbations in Subjects with COPD.”
99.
Chronic Idiopathic Urticaria (Health Outcomes Solutions). Investigator. 2008-2009. “A
Qualitative Telephone Interview Study in Adult Patients with Chronic Idiopathic
Urticaria.”
100.
Chronic Idiopathic Urticaria (Genentech Q4577g). Primary Investigator. 2009 “A Phase
II, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of
Xolair (Omalizumab) in Patients with Chronic Idiopathic Urticaria who Remain
Symptomatic with Antihistamine (H1).”
101.
Asthma (Novartis CIGE025AUS33). Sub-Investigator. 2008-2009. “A 26-week
Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect
of omalizumab on Markers of Asthma Impairment in Patients with Persistent Allergic
Asthma.”
102.
Hereditary Angioedema (ViroPharma 0624-400) Primary Investigator. 2009-2010. “A
Phase IV Study to Evaluate the Safety and Effect of Escalating Doses of Cinryze (C1
inhibitor [Human]) as Prophylactic Therapy in Subjects with Inadequately Controlled
Hereditary Angioedema Attacks.”
103.
Asthma (Molly) Phase II trial. Primary Investigator. 2009-2010. “A Phase II,
Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate
Lebrikizumab (MILR1444A) in Adult patients With Asthma Who Are Not Taking
Inhaled Corticosteroids.”
104.
Acute H1N1 Tamiflu Phase IV trial. Primary Investigator. 2009-2010. “A Randomized,
Multicenter Trial of Oseltamivir Doses of 75 mg for 5 or 10 Days in Influenza Patients
with pandemic (H1N1) 2009.”
Richard G. Gower, M.D.
36
105.
COPD Phase III trial. Sub-Investigator. 2009-2010. “A 52-week Efficacy and Safety
Study to Compare the Effect of Three Dosage Strengths of Fluticasone
Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of
Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD).”
106.
COPD Phase III trial. Sub-Investigator. 2009-2010. “Phase III, One-Year, randomized,
Open-label Safety and Patient Acceptability Study of Combivent Respimat (ipatropium
bromide and albuterol sulfate) (20/100 mcg) Inhalation Spray in Comparison to
Combivent Inhalation Aerosol (36/206 mcg) and the Free Combination of Atrovent HFA
(ipatropium bromide HFA) Inhalation Aerosol (34 mcg) and Albuterol HFA Inhalation
Aerosol (180 mcg) in Adults with Chronic Obstructive Pulmonary Disease (COPD).”
107. Perennial Allergic Rhinitis (PAR) Phase III trial. Primary Investigator 2009-2010.
“Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of
MP03-36 (0.15% solution) and MP03-33 (0.10% solution) in Children Ages ≥6 to <12
with Perennial Allergic Rhinitis.”
108.
Hereditary Angioedema (ViroPharma 0624-200) Phase II trial. Primary Investigator.
2010-2011. “An open-label, multiple-dose study to evaluate the safety, pharmacokinetics,
and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze™
in adolescents and adults with hereditary angioedema (Protocol 0624-200).”
Richard G. Gower, M.D.
37
109.
Pediatric Asthma. (Astra-Zeneca AB D589GC00001) Primary Investigator. 2010. “A
Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter
study, comparing budesonide pMDI 160 μg bid with placebo: a 6-week efficacy and
safety study in children aged 6 to <12 years with asthma.”
110.
Allergic Conjunctivitis (ISTA S00041) Phase II trial. Primary Investigator. 2010. “A
randomized, double-masked, placebo-controlled, parallel group confirmatory natural
exposure study of the safety and effectiveness of Bepreve (bepotastine besilate
ophthalmic solution) 1.5% for the treatment of seasonal allergic conjunctivitis associated
with nasal allergy symptoms.”
111.
COPD. Sub Investigator. 2010. “A Randomized, Double-Blind, Parallel Group,
Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination
Product 250/50mcg BID (Advair Diskus) in Comparison to Salmeterol 50 mcg BID
(Serevent Diskus) on the Rate of Exacerbations of Chronic Obstructive Pulmonary
Disease (COPD) Following Hospitalizations.”
112.
COPD. (Boerhinger Ingelheim) Sub-Investigator. 2010. A COPD study comparing
Tiotropium handihaler vs. Tiotropium Respimat.
113.
Asthma (Biota) Primary Investigator. 2010. “A Phase 2 Multicenter, Randomized,
Double-Blinded, Placebo-Controlled, Study of BTA798 in Asthmatic Adults with
Symptomatic Human Rhinovirus Infection.”
114.
CIU (Genentech) Primary Investigator. 2011. “A Phase III, multicenter randomized,
double blind, dose ranging placebo controlled study to evaluate the efficacy response
duration and safety of Xolair in patients with chronic idiopathic urticaria who remain
symptomatic despite antihistamine treatment.”
115.
Hereditary Angioedema (ViroPharma). Primary Investigator. 2011. “Open label single
dose study to evaluate the response and pharmacokinetics/pharmacodynamics of different
doses of Cinryze for treatment of acute Angioedema attacks in children less than 12 years
of age with hereditary Angioedema.”
Richard G. Gower, M.D.
38
REFERENCES:
Henry N. Claman, M.D., Professor, Division of Allergy and Clinical
Immunology, University of Colorado Medical Center, 4200
East Ninth Avenue, Denver, Colorado 80220.
Patrick O. Tennican, M.D., Associate Professor of Medicine, former
head of Internal Medicine Residency Program, Sacred Heart
Medical Center, West 105 Eighth Avenue, Spokane,
Washington, 99204.
Richard B. Byrd, M.D., Clinical Associate Professor of Medicine,
University of Washington, Department of Medicine, Rockwood
Clinic, East 400 Fifth Avenue, Spokane, Washington 99202.
Richard G. Gower, M.D.
39